-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: China Council for the promotion of drugs August 6, 2014 Raptor pharmaceutical company announced that EU has awarded the qualification of cysteamine tartrate orphan drug, the active ingredient of which is rp103, which is used to treat Huntington's disease The decision was made after the Committee on orphan drug products gave a positive opinion in June Christopher Starr, CEO of raptor, said: "this authorization decision is an important milestone in promoting the approval of rp103 for the treatment of Huntington's disease in Europe." Orphan drug qualification allows Raptor to have a 10-year market monopoly in Europe after the drug is approved for marketing 、 http://